RhythmAnalytics vs AI-CVD

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

RhythmAnalytics

by Biofourmis Singapore Pte.

AI-CVD

by HeartLung Corporation

AI Verdict

RhythmAnalytics is an AI-powered tool for automated interpretation of cardiac arrhythmias from single-lead ECG data, providing clinical decision support for rhythm disorders. In contrast, AI-CVD is an AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, focusing on structural risk factors. While both are FDA-cleared Cardiology AI tools, they address different clinical needs using distinct data modalities.

Choose RhythmAnalytics if…

Choose RhythmAnalytics if your primary need is automated, AI-powered interpretation of single-lead ECG data for the detection and classification of various cardiac arrhythmias. This tool is ideal for clinical settings requiring real-time or near real-time analysis of ECGs from devices like Holter monitors, event recorders, or wearable sensors to provide immediate clinical decision support for arrhythmia management.

View RhythmAnalytics →

Choose AI-CVD if…

Choose AI-CVD if you aim to opportunistically screen for cardiovascular and multisystem diseases using existing chest and abdominal CT scans without requiring additional imaging or patient procedures. This platform is best suited for identifying hidden health risks such as coronary artery calcium, aortic calcification, or abnormal cardiac chamber volumes by leveraging routine CT scans already performed for other indications.

View AI-CVD →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	RhythmAnalytics	AI-CVD
Pricing	Contact vendor	Contact for pricing
Deployment	Cloud-based API	Cloud
FDA Status	1 AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AI-CVD

AI-CVD (Tool B) offers high usability by performing opportunistic screening from existing CT scans, requiring no additional imaging, radiation, contrast, or workflow disruption. This seamless integration into current clinical workflows minimizes the burden on both patients and providers. RhythmAnalytics (Tool A), while cloud-based, requires integration via an API and compatibility with specific ECG devices, which may involve more setup.

Clinical Value

AI-CVD

AI-CVD (Tool B) provides broad clinical value by opportunistically screening for a wide range of cardiovascular and multisystem diseases, including CAC scoring, cardiac chamber volumetry, and bone mineral density, from existing CT scans. This enables early detection of hidden risks without new procedures, offering a comprehensive preventive approach. RhythmAnalytics (Tool A) focuses on the interpretation of cardiac arrhythmias, which is valuable but more specialized.

Pricing & Value

Tie

Both RhythmAnalytics (Tool A) and AI-CVD (Tool B) require contacting the vendor for pricing information. Without transparent pricing or detailed return on investment studies for either tool, it is not possible to definitively compare their pricing and overall value.

Enterprise Readiness

RhythmAnalytics

RhythmAnalytics (Tool A) explicitly states it is HIPAA compliant and offers a cloud-based API for integration into medical devices and other ECG systems, indicating a clear path for enterprise adoption and secure data handling. While AI-CVD (Tool B) is FDA-cleared and cloud-based, its HIPAA and BAA compliance are listed as 'likely, contact vendor,' suggesting less explicit readiness for enterprise-level agreements.

Innovation

AI-CVD

AI-CVD (Tool B) demonstrates greater innovation by leveraging AI for opportunistic screening of multiple cardiovascular and systemic diseases from existing CT scans, extracting new insights without additional procedures or workflow disruption. This approach maximizes the value of already acquired data. RhythmAnalytics (Tool A) offers valuable AI-powered ECG interpretation, but this application of AI is a more established area within healthcare.

Support & Docs

RhythmAnalytics

RhythmAnalytics (Tool A) is part of Biofourmis, a larger and more established digital therapeutics company that offers a comprehensive platform with features like physician dashboards and clinical services. This suggests a more robust and structured support and documentation ecosystem. HeartLung Corporation (Tool B), while innovative, does not provide readily available details on its support and documentation infrastructure.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	RhythmAnalytics	AI-CVD
Tool Name	RhythmAnalytics	AI-CVD
Company	Biofourmis Singapore Pte.	HeartLung Corporation
Primary Function	AI-powered automated interpretation of cardiac arrhythmias from single-lead ECG data for clinical decision support.	AI-powered quantitative imaging platform for opportunistic screening for cardiovascular and multisystem diseases using existing CT scans.
Input Data Type	Single-lead ECG data	Existing CT scans (chest and abdominal)
Key Area of Analysis	Cardiac arrhythmias (e.g., AFib, ventricular arrhythmias, ectopic beats), ECG signal processing, QRS feature extraction, heart rate, rhythm analysis.	CT-derived anatomical and density-based measurements, Coronary Artery Calcium (CAC) scoring, Aortic/Mitral valve calcium analysis, Cardiac chamber volumetry, Epicardial fat volumetry, Aorta and pulmonary artery sizing.

Videos

Demos, reviews, and walkthroughs featuring RhythmAnalytics and AI-CVD.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What type of patient data does each tool analyze?

RhythmAnalytics by Biofourmis analyzes single-lead ECG data to interpret cardiac arrhythmias. AI-CVD from HeartLung Corporation, on the other hand, performs opportunistic screening using existing chest and abdominal CT scans to detect cardiovascular and multisystem diseases.

What specific conditions or risks does each tool help detect?

RhythmAnalytics focuses on the automated interpretation and detection of over 15 types of cardiac arrhythmias, including AFib, ventricular arrhythmias, and ectopic beats. AI-CVD identifies hidden health risks by providing automated CT-derived measurements for conditions such as Coronary Artery Calcium (CAC) scoring, aortic valve calcium, cardiac chamber volumetry, and epicardial fat volumetry.

How does each tool integrate into existing clinical workflows?

RhythmAnalytics is a cloud-based API designed for integration with FDA-cleared ECG devices, offering automated interpretation and clinical decision support. AI-CVD is a cloud-based platform that performs opportunistic screening from existing CT scans, requiring no additional imaging, radiation, contrast, or workflow disruption.

What are the primary outputs or measurements provided by each tool?

RhythmAnalytics provides AI-based automated interpretation of cardiac arrhythmias, including beat-by-beat morphology computation, QRS detection, and rhythm analysis. AI-CVD offers automated CT-derived anatomical and density-based measurements such as CAC scoring, cardiac chamber volumetry (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle), epicardial fat volumetry, and aorta and pulmonary artery sizing.

Does either tool require additional imaging or patient exposure?

RhythmAnalytics processes data from existing single-lead ECG devices. AI-CVD explicitly states that it performs opportunistic screening using existing CT scans and requires no additional imaging, radiation, contrast, or workflow disruption.